Capsugel acquires Monash University's proprietary ionic liquids technology

US capsule technology company Capsugel has acquired the intellectual property relating to proprietary Ionic Liquids Technology developed at the Monash Institute of Pharmaceutical Sciences (MIPS) in Australia.

This novel technology uses lipid-like counter-ion salts to improve the solubility of drugs in lipid-based liquid, semi-solid and multiparticulate formulations. This technology adds to Capsugel Dosage Form Solutions’ growing suite of bioavailability enhancement technologies and capabilities.

Under the terms of the agreement, Monash University will transfer its patent application and associated results to Capsugel, effective immediately. Capsugel will also extend its existing partnership with MIPS by funding additional research positions to accelerate ongoing and future drug-delivery projects. Details of the terms of the agreement were not disclosed.